Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm
Open Access
- 19 December 2016
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 28 (3) , 673-675
Abstract
Pembrolizumab, an anti-PD 1 antibody, has been approved for the treatment of metastatic melanoma [1, 2], non-small cell lung carcinoma [3, 4], and head and neck cancers [5]; and is being investigated in other cancers. We describe a case of Pembrolizumab induced severe bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.Keywords
This publication has 7 references indexed in Scilit:
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortJournal of Clinical Oncology, 2016
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyEuropean Journal of Cancer, 2016
- FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1The Oncologist, 2016
- Pembrolizumab-induced necrotic myositis in a patient with metastatic melanomaAnnals of Oncology, 2016
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialThe Lancet, 2014